Zai Lab (ZLAB) Stock Forecast, Price & News

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab or view top-rated stocks.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Zai Lab.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, March, 1st. The company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.58. The business earned $44.17 million during the quarter, compared to analysts' expectations of $54.78 million. Zai Lab had a negative trailing twelve-month return on equity of 37.26% and a negative net margin of 324.08%.
View Zai Lab's earnings history.

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab updated its first quarter earnings guidance on Tuesday, May, 10th. The company provided EPS guidance of ($0.86) for the period, compared to the consensus estimate of ($1.23). The company issued revenue guidance of $46.7 million, compared to the consensus revenue estimate of $45.72 million.

What price target have analysts set for ZLAB?

5 equities research analysts have issued 1-year target prices for Zai Lab's shares. Their forecasts range from $64.00 to $193.00. On average, they expect Zai Lab's share price to reach $117.50 in the next year. This suggests a possible upside of 232.4% from the stock's current price.
View analysts' price targets for Zai Lab or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:

• Dr. Ying Du Ph.D., Founder, Chairperson & CEO (Age 56, Pay $1.38M)
• Mr. Ki Chul Cho, Chief Financial Officer (Age 44, Pay $624.96k)
• Mr. Frazor Titus Edmondson III, Chief Legal Officer & Corp. Sec. (Age 56, Pay $707.3k)
• Dr. Alan Bart Sandler M.D., Pres & Head of Global Devel. in Oncology (Age 65, Pay $545k)
• Ms. Ann Beasley, Chief Compliance Officer
• Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 57)
• Dr. Jonathan J. Wang M.B.A., MBA, Ph.D., Exec. VP & Head of Bus. Devel. (Age 40)
• Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 58)
• Dr. Harald Reinhart M.D., Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases (Age 70) (LinkedIn Profile)
• Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 51)

Who are some of Zai Lab's key competitors?

Some companies that are related to Zai Lab include Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), Acerus Pharmaceuticals (ASPCF), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Intra-Cellular Therapies (ITCI) and Ionis Pharmaceuticals (IONS).
View all of ZLAB's competitors.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (8.57%), BlackRock Inc. (4.07%), Viking Global Investors LP (3.25%), Baillie Gifford & Co. (2.83%), Vanguard Group Inc. (2.34%) and Segantii Capital Management Ltd (2.34%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends for Zai Lab.

Which major investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Baillie Gifford & Co., Brilliance Asset Management Ltd., State Street Corp, Tree Line Advisors Hong Kong Ltd., JPMorgan Chase & Co., Group One Trading L.P., and Goldman Sachs Group Inc.. Company insiders that have sold Zai Lab company stock in the last year include Harald Reinhart, John D Diekman, Tao Fu, William Ki Chul Cho, William Lis, and Ying Du.
View insider buying and selling activity for Zai Lab or view top insider-selling stocks.

Which major investors are buying Zai Lab stock?

ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Invesco Ltd., Segantii Capital Management Ltd, Genesis Investment Management LLP, Woodline Partners LP, Zeal Asset Management Ltd, BlackRock Inc., and Bridgewater Associates LP.
View insider buying and selling activity for Zai Lab or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $35.35.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $3.46 billion and generates $144.31 million in revenue each year. The company earns $-704.47 million in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 1,951 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588, via email at [email protected], or via fax at 86-21-6163-2570.